These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Diagnostic validity of hepatocyte growth factor as marker for rejection in the follow-up of patients after heart transplantation.
    Author: Zwirska-Korczala K, Zakliczyński M, Berdowska A, Zembala M, Jochem J, Gajewska K.
    Journal: J Heart Lung Transplant; 2005 Apr; 24(4):411-5. PubMed ID: 15797741.
    Abstract:
    BACKGROUND: Hepatocyte growth factor (HGF) is a member of growth factor with a variety of known activities, including angiogenesis promotion and antiapoptotic action. It prevents acute graft-versus-host disease after bone marrow transplantation and prolongs allogenic graft survival in rats. The aim of the study was to investigate the relationship between serum HGF concentration and the grade of acute cellular rejection of heart transplant. METHODS: We studied 68 male heart recipients. All of them received triple-drug immunosuppression: cyclosporine A, prednisone, and azathioprine or mycofenolate mofetil. All patients were without signs of heart failure. Blood samples were taken before elective ambulatory endomyocardial biopsy. Biopsy specimens were graded with the International Society for Heart and Lung Transplantation scale. Acute cellular rejection grade 3A and higher were considered as significant. Measurement of serum HGF was made by enzyme-linked immunosorbent assay. RESULTS: We found a positive relationship between serum HGF levels and grade of cellular rejection. As an indicator for the detection of cell rejection processes, HGF with cutoff 2000 pg/ml seems to be useful. CONCLUSIONS: The results of this study demonstrate that HGF can be useful as an indicator for heart graft cell rejection.
    [Abstract] [Full Text] [Related] [New Search]